275 related articles for article (PubMed ID: 7761092)
1. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers.
Clark GJ; Kinch MS; Gilmer TM; Burridge K; Der CJ
Oncogene; 1996 Jan; 12(1):169-76. PubMed ID: 8552388
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
6. TC21 and Ras share indistinguishable transforming and differentiating activities.
Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
[TBL] [Abstract][Full Text] [Related]
7. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
8. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
[TBL] [Abstract][Full Text] [Related]
9. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
10. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
Cox AD; Brtva TR; Lowe DG; Der CJ
Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
[TBL] [Abstract][Full Text] [Related]
11. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
Movilla N; Crespo P; Bustelo XR
Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
[TBL] [Abstract][Full Text] [Related]
12. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
13. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
14. Guanine nucleotide exchange factors: activators of Ras superfamily proteins.
Overbeck AF; Brtva TR; Cox AD; Graham SM; Huff SY; Khosravi-Far R; Quilliam LA; Solski PA; Der CJ
Mol Reprod Dev; 1995 Dec; 42(4):468-76. PubMed ID: 8607978
[TBL] [Abstract][Full Text] [Related]
15. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
[TBL] [Abstract][Full Text] [Related]
17. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
19. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
Saez R; Chan AM; Miki T; Aaronson SA
Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
